Bisdas S, Rumboldt Z, Wagenblast J, Baghi M, Koh T S, Hambek M, Vogl T J, Mack M G
Department of Radiology, Johann Wolfgang Goethe University, Frankfurt, Germany.
AJNR Am J Neuroradiol. 2009 Apr;30(4):793-9. doi: 10.3174/ajnr.A1449.
Perfusion CT (PCT) provides a rapid, reliable, and non-invasive technique for assessing tumor vascularity. The purpose of this study was to assess whether pretreatment dynamic perfusion CT (PCT) may predict response to induction chemotherapy and midterm progression-free survival (PFS) in advanced oropharynx squamous cell carcinoma (SCCA) and to compare the results with those derived by tumor volume measurements.
Nineteen patients underwent routine contrast-enhanced CT (CECT), pretreatment PCT, and conventional endoscopy. Tumor response was determined according to radiologic (RECIST) criteria. The PCT parameters, tumor volume, radiologic response, and PFS were analyzed with use of Cox-proportional hazards model, receiver operating characteristic (ROC), and Kaplan-Meier analysis.
The baseline blood flow (BF), blood volume (BV), and permeability surface area product (PS) were significantly higher, whereas mean transit time (MTT) was significantly lower in the responders than in the nonresponders (P < or = .002). BV showed 100% sensitivity, MTT and PS had the highest specificity (100%), and BF showed 84.2% sensitivity and 66.7% specificity for prediction of tumor response after induction chemotherapy. The pretreatment tumor volume correlated with PFS in the pooled patients group (r = 0.4; P < .0001), whereas postinduction tumor volume correlated significantly with PFS in the responders and nonresponders (r = 0.22-0.64; P < or = .006). Pretreatment tumor volume (P = .0001) and BF (P = .001) were significant predictors for PFS.
Pretreatment PCT parameters may predict response after induction chemotherapy. Tumor volume and BF values may predict PFS in patients with advanced oropharyngeal SCCA.
灌注CT(PCT)为评估肿瘤血管生成提供了一种快速、可靠且无创的技术。本研究的目的是评估在晚期口咽鳞状细胞癌(SCCA)中,治疗前动态灌注CT(PCT)是否可预测诱导化疗的反应及中期无进展生存期(PFS),并将结果与肿瘤体积测量结果进行比较。
19例患者接受了常规增强CT(CECT)、治疗前PCT及传统内镜检查。根据放射学(RECIST)标准确定肿瘤反应。使用Cox比例风险模型、受试者操作特征(ROC)及Kaplan-Meier分析对PCT参数、肿瘤体积、放射学反应及PFS进行分析。
反应者的基线血流量(BF)、血容量(BV)及表面通透性乘积(PS)显著更高,而平均通过时间(MTT)显著低于无反应者(P≤0.002)。BV显示出100%的敏感性,MTT和PS具有最高的特异性(100%),BF对诱导化疗后肿瘤反应预测的敏感性为84.2%,特异性为66.7%。治疗前肿瘤体积与合并患者组的PFS相关(r = 0.4;P < 0.0001),而诱导治疗后肿瘤体积在反应者和无反应者中均与PFS显著相关(r = 0.22 - 0.64;P≤0.006)。治疗前肿瘤体积(P = 0.0001)和BF(P = 0.001)是PFS的显著预测因素。
治疗前PCT参数可预测诱导化疗后的反应。肿瘤体积和BF值可预测晚期口咽SCCA患者的PFS。